2009
DOI: 10.1159/000226288
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Objective: The purpose of this study was to determinewhether or not imatinib mesylate therapy induces growth hormone deficiency (GHD). Subjects and Methods: Seventeen patients with chronic myloid leukemia (CML) were enrolled in the study. The glucagon stimulation test (GST), and standard deviation scores (SDSs) of insulin-like growth fac- tor 1 (IGF-I) and insulin-like growth factor binding protein (IGFBP-3) were used to determine GHD. The L-dopa test was performed on those with IGF-I SDSs above the –1.8 cut-o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
16
0
1

Year Published

2010
2010
2016
2016

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 21 publications
(19 citation statements)
references
References 24 publications
(17 reference statements)
2
16
0
1
Order By: Relevance
“…A number of studies have reported impaired longitudinal growth in children with CML treated with TKIs. [10][11][12][13][14][15][16][17][18] Hobernicht et al described the case of a 7-year-old identical twin whose linear growth decreased from the 95th percentile to the 25th percentile 4 years after initiation of imatinib. [12] Her unaffected twin sister's growth remained at the 95th percentile.…”
Section: Growth Impairment and Growth Hormone Axis Abnormalitiesmentioning
confidence: 99%
See 3 more Smart Citations
“…A number of studies have reported impaired longitudinal growth in children with CML treated with TKIs. [10][11][12][13][14][15][16][17][18] Hobernicht et al described the case of a 7-year-old identical twin whose linear growth decreased from the 95th percentile to the 25th percentile 4 years after initiation of imatinib. [12] Her unaffected twin sister's growth remained at the 95th percentile.…”
Section: Growth Impairment and Growth Hormone Axis Abnormalitiesmentioning
confidence: 99%
“…The exact mechanism underlying growth failure with TKI treatment is unclear, but it appears to be due to inhibition of activity at non‐BCR‐ABL1 sites, which leads to abnormalities in PDGFR‐β signaling and results in decreased recruitment and activity of chondrocytes in the growth plate . The growth hormone (GH)–insulin‐like growth factor‐1 (IGF‐1) axis may also be altered by TKIs, which is addressed below …”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…Interferon and interleukins have been implicated for both primary and central hypothyroidism. Imatinib mesylate, a tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia and some sarcomas (GIST), has been shown to cause GHD and subclinical glucocorticoid deficiency in a significant number of patients on stimulation test [55,56]. mTOR inhibitors have been demonstrated to cause antiproliferative and radiosensitizing activity on pituitary adenoma cells, and rat GH3 or MMQ cell lines [57].…”
Section: Reviewmentioning
confidence: 99%